Biotricity (NASDAQ:BTCY) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.36) by 30.56 percent. The company reported quarterly sales of $3.200 million which met the analyst consensus estimate. This is a 16.79 percent increase over sales of $2.740 million the same period last year.
Biotricity Q4 2024 Adj EPS $(0.47) Misses $(0.36) Estimate, Sales $3.200M Inline
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.